INHIBRX BIOSCIENCES, INC. Long-Term Debt
INHIBRX BIOSCIENCES, INC. (INBX) had Long-Term Debt of $176.28 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-13
- 2026-06-30: Long-term Debt, Excluding Current Maturities $176.28M.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $174.99M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $100.56M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $99.92M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-06-30 | $176.28M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $174.99M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $100.56M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $99.92M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $99.28M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $98.65M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 |
| 2023-12-31 | $206.97M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |